glp·helper
glphelper.com/semaglutide/nebraska/lincoln
GLP-1 receptor agonistFDA-approved December 2017 (Ozempic) · June 2021 (Wegovy)Rx · Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)

Semaglutide® providers &
prescriptions in Lincoln, NE

Verified Semaglutide providers in Lincoln, NE. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

city providers
30
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Nebraska
30 of 30 shown

Find a Semaglutide provider in Nebraska.

Every entry is checked against the NPI registry and the Nebraska medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Nebraska city · /semaglutide/nebraska/{city}
§ 03Getting Semaglutide in Lincoln
30 providers · Lincoln, NE

How to get Semaglutide in Lincoln.

30 GLP-1 prescribers and 7 local resource types are on record for Lincoln, plus 1 nearby town in the directory.

Prescribers in Lincoln
30 prescribers
30 GLP-1 prescribers in Lincoln, most listed as Family Medicine (15), Internal Medicine (9) and Internal Medicine, Endocrinology, Diabetes & Metabolism (6). Any Nebraska-licensed physician, nurse practitioner, or PA can prescribe Semaglutide, over video or in person. The nearest towns on record are Omaha (34 providers).
Around the prescription in Lincoln
7 listed nearby
6 dietitians, 6 nutritionists, 6 gyms, 6 fitness clubs, 5 trainers, 6 physiotherapists and 6 places to move are on record near Lincoln.
Medicaid (weight loss)
Diabetes only
As of April 2026, Nebraska Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Nebraska’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

The molecule in Ozempic, Rybelsus, and Wegovy. The brands differ in approved use and maximum dose.

Semaglutide is a once-weekly GLP-1 receptor agonist sold under three brand names by Novo Nordisk: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management. It mimics a gut hormone that signals satiety to the brain and slows gastric emptying. The injectable forms share the same molecule; only the approved indication and maximum dose differ.[2][3]

In the STEP-1 obesity trial, adults without diabetes taking Wegovy (semaglutide 2.4 mg) lost a mean of 14.9% of body weight at 68 weeks versus 2.4% with placebo. In the SELECT trial, semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease but without diabetes.[1]

At a glanceMultiple (brand-specific)
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
December 2017 (Ozempic) · June 2021 (Wegovy)
Approved use
Type 2 diabetes (Ozempic/Rybelsus) · chronic weight management (Wegovy)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)
Available doses
0.25 mg · 0.5 mg · 1 mg · 1.7 mg · 2.4 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy

Community health · CDC

Weight & metabolic health in Nebraska

Diagnosed diabetes reaches 9.7% of adults in Nebraska.

of Nebraska adults have obesity
37.6%
diagnosed diabetes
9.7%

Age-adjusted estimates for Nebraska, community figures, not individual risk. CDC BRFSS 2024.

Estimate your weight lossthe GLP-1 side-effect timeline
§ 05Support around Semaglutide in Lincoln
6 nutritionists

The prescription is one part. Here is the rest, in Lincoln.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Lincoln, NE, ordered as the registry lists them, never by who pays us.

Nutritionists

A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.

Jennifer Bartles, LMNT, RD, CDE
NUTRITIONIST
Nutritionist
8207 Northwoods Dr Ste 100
Call 402-484-3440NPI 1588236871
Jordan Bontrager, RD LMNT
NUTRITIONIST
Nutritionist
6829 N 72Nd St Ste 4500
Call 402-717-1299NPI 1477184018
Tammy Burton-Fikar, MPH RDN LMNT
NUTRITIONIST
Nutritionist · Education
3763 39Th Ave Ste 400
Call 402-563-0312NPI 1598224842
Sarah Burwell
NUTRITIONIST
Nutritionist
4055 Yankee Hill Rd
Call 402-328-6300NPI 1649038621
Lynette Hahne, RD, LMNT
NUTRITIONIST
Nutritionist
7441 O St
Call 402-484-5600NPI 1336441914
Ellen Roufs, FNTP
NUTRITIONIST
Nutritionist · Education
407 N 26Th St Apt 1
Call 507-766-4078NPI 1093480345

Gyms near you

A gym gives you the regular movement that keeps muscle while the weight comes off.

Genesis Health Clubs, East Lincoln
GYM
4.5 on Google · 730 reviews
1305 S 70th St
Website
Genesis Health Clubs - O Street
GYM
4.5 on Google · 682 reviews
6140 O St
Website
Planet Fitness
GYM
4.4 on Google · 582 reviews
3020 Folkways Blvd
Website
Crunch Fitness - Lincoln
GYM
4.4 on Google · 517 reviews
5050 N 27th St
Website
Genesis Health Clubs - Racquet Club
GYM
4.4 on Google · 464 reviews
5300 Old Cheney Rd
Website
VASA Fitness
GYM
4.1 on Google · 454 reviews
4615 Vine St
Website
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the STEP weight-management program, the SUSTAIN diabetes program, and the SELECT cardiovascular outcomes trial. Figures are means at each trial's primary endpoint.

STEP-1 randomized 1,961 adults with overweight or obesity (without diabetes) to semaglutide 2.4 mg or placebo for 68 weeks. Mean weight change was −14.9% with semaglutide versus −2.4% with placebo; 86% of treated patients lost ≥5% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (Wegovy 2.4 mg)
−14.9%
STEP-1, 68 wk vs −2.4% placebo[2]
Patients losing ≥5% body weight
86%
STEP-1, 2.4 mg[2]
Major adverse cardiac events
−20%
SELECT, HR 0.80[3]
HbA1c reduction (T2D)
−1.4 to −1.8%
SUSTAIN program[4]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average semaglutide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
20 to 44%
mild
Most common; dose-dependent, usually eases after titration
Diarrhea
20 to 30%
mild
More frequent during dose escalation
Vomiting
16 to 24%
mild
Reduced by slower titration
Constipation
20 to 24%
mild
Abdominal pain
10%
moderate
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
1.6 to 2.6%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash, Wegovy (no insurance)
$1,300 to $1,400
per month
Brand-name retail average[6]
Cash, Ozempic (no insurance)
$950 to $1,150
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Commercial insurance (weight)
Often denied
Wegovy is on-label but frequently requires PA and is denied
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $0 to $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Semaglutide providers in Nebraska

NPI-verified Semaglutide (semaglutide) prescribers and clinics, ordered by availability, never by who pays us.

Semaglutide in other states

Find NPI-verified Semaglutide (semaglutide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Semaglutide in Nebraska

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Semaglutide is the active molecule in all three Novo Nordisk products. Ozempic and Rybelsus are approved for type 2 diabetes; Wegovy is approved for chronic weight management at a higher maximum dose (2.4 mg/week). Insurers treat the brands as separate drugs.[1]